Navigation Links
Cancer research award to Johns Hopkins basic scientist
Date:4/23/2010

Joshua T. Mendell, M.D., Ph.D., an associate professor in the McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine, and a Howard Hughes Medical Institute Early Career Scientist, is the recipient of the 30th annual American Association for Cancer Research Award for Outstanding Achievement in Cancer Research. The award is for his work to advance the understanding of microRNAs (miRNAs), genetic signaling elements involved in gene "silencing," which are important for normal physiology and diseases such as cancer.

The award, which comes with a $5,000 cash prize, was presented during the 101st annual meeting of the American Association for Cancer Research, at which Mendell delivered a lecture, "MicroRNA Reprogramming in Cancer: Mechanisms and Therapeutic Opportunities." His recent research demonstrates that the delivery of microRNAs to cancer cells represents a promising strategy for cancer therapy.

"To be included among the incredible past recipients of this award many of whom I view as scientific role models is truly humbling and very exciting," Mendell says. "This recognition suggests that our work has addressed important scientific questions that have had a broad impact on the cancer research community, and provides inspiration to continue to investigate fundamental questions in cancer biology."

Mendell's research focuses on short pieces of RNA that do not encode protein but control genes. These small molecules can act as either cancer-driving oncogenes or as tumor-suppressor genes, which prevent cells from becoming cancerous. Mendell's laboratory is studying microRNAs in human cells and in animals such as zebrafish and mice to understand how aberrant miRNA activity contributes to cancer and to develop miRNA-based therapeutic strategies.

Mendell earned both his medical degree (2003) and a Ph.D. (2001) at Johns Hopkins before starting his lab there. He has received a number of awards and recognitions, including being named the Outstanding Young Scientist in the State of Maryland (Allan C. Davis Medal), 2007; a "Top Young Investigator of 2007" by Genome Technology Magazine, 2007; a Leukemia and Lymphoma Society Scholar, 2008; and a Howard Hughes Medical Institute Early Career Scientist, 2009.

"We are proud that the AACR has chosen to recognize Josh for his outstanding work," says David Valle, M.D., the Henry J. Knott Professor and Director of the Institute for Genetic Medicine. "The microRNA field has really taken off, and Josh has been there to set the bar."

This year's AACR meeting, themed "Conquering Cancer Through Discovery Research," highlighted novel approaches and technologies being used in the laboratory, innovative preclinical science and clinical trials. As the premier scientific meeting in cancer research, it attracts over 17,000 attendees annually and covers the breadth of cancer science from basic through clinical and epidemiological research.

"AACR member scientists are making great strides in basic, translational and clinical research, as well as population science and prevention," says Margaret Foti, Ph.D., M.D., chief executive officer of the AACR. "Their work is having an enormous impact on the pace of discovery. We are extremely proud to honor their outstanding work because these achievements are saving lives around the world."


'/>"/>

Contact: Maryalice Yakutchik
myakutc1@jhmi.edu
443-287-2251
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Prostate cancer: Risk increases with the number of affected family members
2. Major League Baseball Players Alumni Help Lazarex Cancer Foundation Raise Funds
3. BLUE Buffalo Pet Food and PETCO Partner to Fight Pet Cancer During Pet Cancer Awareness Month
4. Magnitude of overdiagnosis in cancer indicates need for strategies to address the problem
5. MU researchers show potential for new cancer detection and therapy method
6. Remedy Needed for Overdiagnosis of Cancers
7. “An Evening Of Hope” - Tonight is the Official Pre-Event for this Year's American Cancer Society Starry Night Gala
8. Black Women Wait Longer for Breast Cancer Diagnosis, Treatment
9. ASTRO president speaks on prostate cancer at MEDCAC meeting
10. Researchers identify a new breast and ovarian cancer susceptibility gene
11. Few Over 50 Get Skin Cancer Screenings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Maryland (PRWEB) , ... December 06, 2016 , ... ... announced the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for ... health active alerts and even taking an EKG from the watch while sharing ...
(Date:12/6/2016)... ... December 06, 2016 , ... 'Tis the season for ... routines. That means it's also the season when eating healthy, staying active, and taking ... on schedule is harder to do. , "Shopping trips, parties and family gatherings ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana Sibirskaya: A Life Devoted ... of sacrifice and enlightenment. , “Tatiana Sibirskaya: A Life Devoted to ... for creative outlets, Carolyn gravitated toward writing through the inspiration of her aging ...
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class ... . , Mobility Scooters give freedom to people who need help getting around. For ... be facing a long period of rehabilitation after an illness or accident. There is ...
(Date:12/6/2016)... ... 06, 2016 , ... "Add realistic flares and light leaks to your media ... to clip with high quality 4K lens flare footage," said Christina Austin - CEO ... filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel lens flare ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, ... Sankyo) today announced preliminary safety and efficacy data ... investigational oral selective MDM2 inhibitor, suggesting that DS-3032 ... including relapsed/refractory acute myeloid leukemia (AML) and high-risk ... escalation part of the phase 1 study of DS-3032 ...
(Date:12/5/2016)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ... an enhanced technology platform designed with the ability to ... Pyxis™ and Alaris™ systems, at this year,s American ... being held in Las Vegas ... that approximately 68 percent of medication errors occur during ...
(Date:12/5/2016)... Eisai Inc. announced today new analyses and ... of the American Epilepsy Society (AES). ... adjunctive therapy for the treatment of partial onset seizures ... generalized tonic-clonic seizures (PGTC) in patients with epilepsy who ... Important Safety Information for FYCOMPA, including Boxed WARNING for ...
Breaking Medicine Technology: